MUMBAI Biocon(BION.NS), India's top listed biotech firm, plans to launch psoriasis drug Alzumab in the country in the July-September quarter, a top company executive said on Friday.
The company expects sales of 1 billion rupees from the drug over four years, Kiran Mazumdar-Shaw, chairman, Biocon said in a conference call.
Late on Thursday, Biocon reported an 8.24 percent rise in net profit to 920 million rupees for the Oct-Dec quarter compared with a year earlier.
(Reporting by Kaustubh Kulkarni; Editing by Prateek Chatterjee)
CCI fines cement companies $944 million for price fixing
MUMBAI The Competition Commission of India (CCI) has imposed a 63.2 billion rupee ($944 million) fine on 10 cement companies and a trade body for price fixing, the Ministry of Corporate Affairs said a statement.
India accords residency status to foreign investors
NEW DELHI India approved a plan on Wednesday to allow foreign investors to settle, emulating a policy in countries such as the United States and Singapore to woo investment from abroad.
India's fiscal deficit reaches 74 percent of full-year target in July
NEW DELHI India's fiscal deficit during April-July was 3.93 trillion rupees ($58.69 billion), or 73.7 percent of the budgeted target for the fiscal year ending in March 2017, government data showed on Wednesday.